BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis

Immix Biopharma (IMMX)Immix BiopharmaCompany update

- 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) -

- To-date, all patients achieving MRD-negativity reached CR within one year of treatment -

- Across all forty-five patients,...

Related news

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

JNJJohnson & Johnson2026-08-21 09:40 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care

JNJJohnson & Johnson2026-09-25 11:16 EST

Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

KURAKura Oncology2026-09-29 09:15 EST

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

INBXInhibrx2026-09-08 11:30 EST

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-10-05 13:45 EST

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Stock data

Close
9.64 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States